Floatz logo

109 assets in Sarcoma

Therapeutic assets addressing Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cyclophosphamide
Sarcoma
Essen BiotechP2BB (68)
Adriamycin
Sarcoma
City of Hope Medical CenterP3BB (67)
Carboplatin
Sarcoma
OHSU Knight Cancer InstituteP2BB (67)
Cis-Diamminedichloroplatinum Ii
Sarcoma
Roswell Park Cancer InstituteP2BB (67)
Irinotecan
Sarcoma
OHSU Knight Cancer InstituteP3B (63)
Pembrolizumab
Sarcoma
Essen BiotechP2B (63)
Docetaxel
Sarcoma
IGM Biosciences, Inc.P2B (62)
Epirubicin
Sarcoma
EpkinP2B (61)
Alectinib
Sarcoma
OHSU Knight Cancer InstituteP2B (60)
Entrectinib
Sarcoma
OHSU Knight Cancer InstituteP2B (60)
Letrozole
Sarcoma
OHSU Knight Cancer InstituteP2B (60)
(+)-Vincristine
Sarcoma
OHSU Knight Cancer InstituteP2B (60)
Atezolizumab
Sarcoma
Cancer Research UKP2B (59)
Durvalumab
Sarcoma
Second Affiliated Hospital of Guangzhou Medical UniversityP2B (59)
Nivolumab
Sarcoma
Tempest TherapeuticsP2B (59)
Tislelizumab
Sarcoma
HiFiBiO TherapeuticsP2B (59)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer
Sarcoma
Sensei Biotherapeutics, Inc.P2B (58)
Fludarabine
Sarcoma
Essen BiotechP2B (57)
Tamoxifen
Sarcoma
OHSU Knight Cancer InstituteP2B (57)
Vinorelbine Ditartrate
Sarcoma
OHSU Knight Cancer InstituteP1/2B (57)
Fludeoxyglucose
Sarcoma
National Cancer Institute (NCI)P2CCC (55)
Abemaciclib
Sarcoma
OHSU Knight Cancer InstituteP2CCC (53)
Avapritinib
Sarcoma
M.D. Anderson Cancer CenterP2CCC (53)
Eribulin
Sarcoma
OHSU Knight Cancer InstituteP1CCC (53)
Exemestane
Sarcoma
OHSU Knight Cancer InstituteP2CCC (53)
Osimertinib
Sarcoma
OHSU Knight Cancer InstituteP2CCC (53)
Palbociclib
Sarcoma
OHSU Knight Cancer InstituteP1CCC (53)
Rogaratinib
Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Adapt-001
Sarcoma
EpicentRx, Inc.P2CCC (51)
Cabozantinib
Sarcoma
Nationwide Children's HospitalP2CCC (51)
FAPI74
Sarcoma
National Cancer Institute (NCI)P2CCC (51)
Iodized Ethyl Esters Of Poppyseed Fatty Acids
Sarcoma
City of Hope Medical CenterP2CCC (51)
Ipilimumab
Sarcoma
Second Affiliated Hospital of Guangzhou Medical UniversityP1/2CCC (51)
Ivocizumab
Sarcoma
Fudan UniversityP2CCC (51)
Lomustine
Sarcoma
Actuate Therapeutics Inc.P2CCC (51)
Muamycin
Sarcoma
City of Hope Medical CenterP2CCC (51)
Rain-32
Sarcoma
Rain Oncology IncP2CCC (51)
Riluzole
Sarcoma
University of California, IrvineP2CCC (51)
TIL
Sarcoma
Udai KammulaP2CCC (51)
Zanidatamab
Sarcoma
UNICANCERP2CCC (51)
Capecitabine
Sarcoma
OHSU Knight Cancer InstituteP1CCC (50)
Elraglusib
Sarcoma
Actuate Therapeutics Inc.P2CCC (49)
64cu-lnth-1363s
Sarcoma
Lantheus Medical ImagingP1/2CCC (48)
Azacytidine
Sarcoma
National Cancer Institute (NCI)P1/2CCC (48)
Ecubectedin
Sarcoma
Grupo Espanol de Investigacion en SarcomasP1/2CCC (48)
Gotistobart
Sarcoma
OncoC4, Inc.P1/2CCC (48)
Trastuzumab
Sarcoma
OHSU Knight Cancer InstituteP1/2CCC (48)
Pyruvate
Sarcoma
Rigshospitalet, DenmarkP2CC (47)
H-Gamma1 Heavy Chain Homo Sapiens (1-447) [Vh (Homo Sapiens Ighv4-59*01 (99.0%) -(Ighd) -Ighj3*02 (93.3%) T125>I (114), Cdr-Imgt [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo Sapiens Ighg1*01, G1M17,1 Ch1 K120, Ch3 D12, L14, 9-G1V21 Ch2 Y15.1, T16, E18 (Ch1 K120 (214) (118-215), Hinge 1-15 (216-230), Ch2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), Ch3 D12 (356), L14 (358) (341-445), Chs (446-447)) (118-447)], (220-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv3-11*01 (96.8%) -Igkj4*01 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%) Km3 A45.1, V101 (Ckappa A45.1 (153'), V101 (191')) (108'-214')]; Dimer (226-226'':229-229'')-Bisdisulfide, Produced In A Cell Line Derived From Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa
Sarcoma
Kineta Inc.P1/2CC (46)
Spartalizumab
Sarcoma
SOLTI Breast Cancer Research GroupP2CC (46)
Showing 1 to 50 of 109 assets
PreviousPage 1 of 3Next